Modafinil vs Phenylpiracetam
FDA Approved vs Moderate Research
monitor Researched · 90% Both compounds have stimulant properties through partially overlapping mechanisms (dopaminergic enhancement). Combining them can produce excessive stimulation, anxiety, insomnia, and elevated heart rate in sensitive individuals. If combining, reduce the dose of each and monitor closely for overstimulation. Not recommended for routine co-administration.
Molecular Data
Modafinil Phenylpiracetam
Weight 273.35 Da 218.25 Da
Half-life ~12-15 hours ~3-5 hours
Type Diphenylmethylsulfinylacetamide (C15H15NO2S) Racetam derivative (C12H14N2O2)
Key Benefits
Modafinil
01 Sustained wakefulness and alertness for 10-15 hours without the jitteriness of traditional stimulants
02 Enhanced executive function, working memory, and decision-making under fatigue
03 Improved focus and concentration during prolonged cognitive tasks
04 Reduced impulsivity and improved task completion in sleep-deprived individuals
05 Low abuse potential relative to amphetamine-class stimulants (Schedule IV)
06 Minimal impact on normal sleep architecture when taken in the morning
Phenylpiracetam
01 Potent cognitive enhancement including improved memory, focus, and information processing speed
02 Psychostimulant properties that increase motivation, mental energy, and alertness without the jitteriness of classical stimulants
03 Physical performance enhancement through improved stamina, reduced perception of effort, and increased exercise tolerance
04 Enhanced cold tolerance -- a unique property among nootropics, originally developed for extreme-environment performance
05 Anxiolytic effects at standard doses, reducing stress reactivity without sedation
06 Anticonvulsant activity demonstrated in preclinical models
Side Effects
Modafinil
Headache (most frequently reported side effect, often dose-dependent)
Insomnia (particularly if taken too late in the day)
Anxiety and nervousness
Appetite suppression and mild nausea
Dry mouth
Dizziness
Gastrointestinal discomfort (diarrhea, abdominal pain)
Phenylpiracetam
Insomnia, particularly if taken in the afternoon or evening -- the stimulant effects can persist for several hours after dosing
Irritability and overstimulation, especially at higher doses or when combined with other stimulants
Headache, most commonly caused by increased acetylcholine demand without adequate choline supplementation
Rapid tolerance development -- the most significant practical limitation, requiring intermittent dosing schedules to maintain efficacy
Contraindications
Known hypersensitivity to modafinil or armodafinil
History of Stevens-Johnson Syndrome, TEN, or DRESS with prior modafinil/armodafinil use
Severe hepatic impairment (dose reduction required in moderate impairment)
Unstable angina or recent myocardial infarction
Left ventricular hypertrophy or clinically significant mitral valve prolapse with prior stimulant use
Pregnancy (limited human data; animal studies show teratogenicity at high doses)
Known hypersensitivity to phenylpiracetam or other racetams
Severe hypertension or cardiovascular disease (due to stimulant properties)
Pregnancy and breastfeeding (insufficient safety data)
Severe hepatic or renal impairment
Competitive athletes subject to WADA testing (phenylpiracetam is a prohibited substance under Section S6: Stimulants)
Research Evidence
Modafinil Phenylpiracetam
Status FDA Approved Moderate Research
References 5 studies 5 studies
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.